2024

1. A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)

   Gastroenterologia y Hepatologia, Vol. 47, Núm. 8, pp. 821-833

2. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry

   Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74

3. Determinant factors for first-line treatment choice and effectiveness in pediatric eosinophilic esophagitis: an analysis of the EUREOS EoE CONNECT registry

   European Journal of Pediatrics, Vol. 183, Núm. 8, pp. 3567-3578

4. Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU

   Therapeutic Advances in Gastroenterology, Vol. 17

5. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance

   American Journal of Gastroenterology, Vol. 119, Núm. 4, pp. 646-654

6. Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort

   Gastroenterologia y Hepatologia

7. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

   Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

8. HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study of the ENEIDA registry.

   American Journal of Gastroenterology

9. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry

   Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588

10. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 10, pp. 1325-1338

11. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

12. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

    Digestive and Liver Disease, Vol. 56, Núm. 11, pp. 1845-1853

13. Prophylactic versus endoscopy-driven treatment of crohn's postoperative recurrence: A retrospective, multicentric, european study [porcse study]

    Journal of Crohn's and Colitis, Vol. 18, Núm. 8, pp. 1202-1214

14. Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study

    Digestive and Liver Disease, Vol. 56, Núm. 12, pp. 2060-2068

15. Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients

    Inflammatory Bowel Diseases, Vol. 30, Núm. 2, pp. 167-182

16. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

17. Sex-related differences in the presentation, management and response to treatment of eosinophilic esophagitis: Cross sectional analysis of EoE CONNECT registry

    United European Gastroenterology Journal

18. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

19. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5

20. Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU

    Digestive and Liver Disease